NCT07734415Enrolling by invitationPhase 2
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
A Long-term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous IMG-007 in Participants of a Previous IMG-007 Moderate-To-Severe Atopic Dermatitis Clinical Trial
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 11 Jun 2026
- Start date
- 5 Jun 2026
- Primary completion date
- Mar 2028
- Lead sponsor
- Inmagene LLC
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07734415
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 400
- From 5 Jun 2026 to the primary completion date, Mar 2028
- 23 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Enrolling by invitation participants with moderate to severe AD who have completed IMG-007-203
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (23)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.